Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2010

View Archived Issues

Merck & Co.'s new GPR119 agonist lowers blood glucose in murine diabetes model

Angiochem's EPiC platform yields anticancer drugs with improved brain penetration

Renovis identifies novel P2X3 and P2X2/3 receptor antagonists

Janssen discloses novel NOP (ORL1) opioid receptor modulators

University of Central Florida claims new STAT3 inhibitors

Novartis presents novel antibacterial agents

Institute for OneWorld Health claims novel CFTR inhibitors

AD5-10: new option for treatment of ovarian cancer

Celgene and Agios collaborate to develop cancer metabolism programs

Advaxis begins phase II trial of ADXS11-001 in cervical dysplasia

Impax completes enrollment in phase III IPX-066 trial in Parkinson's disease

Genocea and U.S. military to collaborate on development of malaria vaccine

Mirabegron well tolerated and improves overactive bladder variables in large study

Studies on progesterone caproate for prevention of preterm birth

Rexahn reports phase IIa Serdaxin data in major depressive disorder

Impax amends copromotion agreement with Wyeth

D-Pharm receives agreement letter on SPA for phase III DP-b99 trial in acute ischemic stroke

Alexion's Soliris approved in Japan for paroxysmal nocturnal hemoglobinuria

PhytoMedical signs letter of intent with Medicilon for studies on brain cancer drug candidate

Updated phase I data presented on JI-101 in solid tumors

Diquas ophthalmic solution approved in Japan for dry eye treatment

Sandoz to acquire Oriel Therapeutics

Cell Therapeutics nears MAA submission for pixantrone in E.U.

FDA approves Tarceva as maintenance therapy for advanced non-small cell lung cancer

Cannasat Therapeutics becomes Cynapsus Therapeutics

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...